FUJIFILM Snags FDA Clearance for Latest Innovation in PACS Technology: Synapse 5
STAMFORD, Conn., Feb. 17, 2016 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, announced it has received FDA 510 (k) clearance for the sale and distribution of its most recent innovation in PACS technology, Synapse 5. The latest offering of Fujifilm's comprehensive Synapse line of solutions that also includes VNA, 3D, RIS, cardiovascular and mobile offerings will transform healthcare organizations as they enhance collaboration and optimize workflows across healthcare facilities. Synapse 5 will be on display at the Healthcare Informatics Management Systems Society (HIMSS) 2016 conference and exhibition held February 29 - March 4, 2016 in Las Vegas, Nevada.
"As reimbursement continues to move from volume-driven to value-based, radiologists need to boost their efficiency, their productivity and their accuracy. The challenge is to be a speed reader who, despite the high velocity, doesn't miss a single abnormality on a single study," said Johann Fernando, Ph.D., chief operating officer at FUJIFILM Medical Systems U.S.A., Inc. "Synapse 5 is designed to help our customers keep up with the changes that have already taken place and, more importantly, to help them stay out ahead of what comes next."
Fujifilm's large base of current PACS customers will be able to take advantage of the speed of Synapse 5 through an upgrade to their current system. It will deliver a server-side, zero-download viewer utilizing a browser-independent desktop experience. Synapse 5 stands to save organizations significant resources due to less desktop management, and a dramatic reduction in bandwidth requirements which many are currently consuming today with last generation PACS technology.
"Synapse 5 has the potential to be a disruptive technology in the PACS market. It truly addresses all of the challenges customers face today from the management of desktop clients to reading large data sets," said Bill Lacy, division vice president of Informatics Marketing and Enterprise Sales at FUJIFILM Medical Systems U.S.A., Inc. "Synapse 5 will provide our customers with solutions to work remotely and across multiple locations and will satisfy the performance demands."
Synapse 5 was introduced at the 2015 scientific assembly and annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL. Synapse 5 will be available for commercial release in the U.S. market in the second half of 2016.
To register for a product demonstration at HIMSS, please click here.
For more information about Fujifilm's comprehensive Synapse line of solutions, please visit: http://www.fujifilmusa.com/products/medical/medical-informatics/
About Fujifilm
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women's health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. The TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit: www.fujifilmhealthcare.com and www.fujifilmendoscopy.com.
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fujifilm-announces-fda-510k-clearance-for-latest-innovation-in-pacs-technology-synapse-5-300221735.html
SOURCE FUJIFILM Medical Systems U.S.A., Inc.
